![Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/e7d31c91-9c6a-4ecc-87eb-2074454af216/gr1a.jpg)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
![Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d763732d-acff-446e-872e-e81d6e44f06f/gr1_lrg.jpg)
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine
![Data Safety and Monitoring Boards Should Be Required for Both Early- and Late-Phase Clinical Trials - ScienceDirect Data Safety and Monitoring Boards Should Be Required for Both Early- and Late-Phase Clinical Trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2452302X21002990-fx1.jpg)
Data Safety and Monitoring Boards Should Be Required for Both Early- and Late-Phase Clinical Trials - ScienceDirect
Lost in translation? – How you can smoothly progress to clinical development and beyond - Biopharma Excellence
![Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study) - eClinicalMedicine Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study) - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b50c42ef-4067-4872-8d60-055d073801bc/gr1a.jpg)
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study) - eClinicalMedicine
![PDF] Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug PDF] Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug](https://d3i71xaburhd42.cloudfront.net/f3aedb5d20e731efe213af1f3733f00ec267e1a6/6-Figure3-1.png)
PDF] Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug
![Understanding Clinical Trial Terminology: What's a Phase 1, 2 or 3 Clinical Trial? - Concert Pharmaceuticals Understanding Clinical Trial Terminology: What's a Phase 1, 2 or 3 Clinical Trial? - Concert Pharmaceuticals](https://www.concertpharma.com/wp-content/uploads/2019/09/9-3-19-Persepectives-blog-What-is-Phase-1-2-3-image-for-9-3-19-final-.jpg)